Essais liés19clinical trials
VilleMiamilocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT03489278

Ouvrir le site du centre

Essais cliniques associés

19
MoléculeIndication / populationPhaseNCTTitreStatut
Lab Assay for seven genetic variants for Parkinson's Disease Parkinson À vérifier NCT04994015 Parkinson's Foundation PD GENEration Genetic Registry RECRUITING
BHV-7000 Épilepsie Phase 2/3 NCT06132893 RISE 2 — A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy RECRUITING
PGB2 — Phenotype, Genotype and Biomarkers 2 Sclérose latérale amyotrophique À vérifier NCT04875416 PGB2 — Phenotype, Genotype and Biomarkers 2 ACTIVE_NOT_RECRUITING
Phenotype, Genotype & Biomarkers in ALS and Related Disorders Sclérose latérale amyotrophique À vérifier NCT02327845 Phenotype, Genotype & Biomarkers in ALS and Related Disorders ACTIVE_NOT_RECRUITING
TRIAL READY (Clinical Trial Readiness) Sclérose latérale amyotrophique À vérifier NCT03912987 TRIAL READY (Clinical Trial Readiness) ACTIVE_NOT_RECRUITING
CAPTURE-ALS — Clinical Procedures to Support Research in ALS Sclérose latérale amyotrophique À vérifier NCT03489278 CAPTURE-ALS — Clinical Procedures to Support Research in ALS RECRUITING
VHB937 Sclérose latérale amyotrophique Phase 2 NCT06643481 ASTRALS — A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) ACTIVE_NOT_RECRUITING
Acoramidis Alzheimer Phase 3 NCT06563895 Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant RECRUITING
TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial SEP Non applicable NCT03500328 TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial ACTIVE_NOT_RECRUITING
COYA 302 Sclérose latérale amyotrophique Phase 2/3 NCT07161999 ALSTARS — Study of COYA 302 for the Treatment of ALS RECRUITING
Standard lymphodepletion regimen Myasthénie Phase 2/3 NCT06193889 KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis RECRUITING
Vamorolone Myopathies À vérifier NCT06564974 DMD-001 SUMMIT — Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT RECRUITING
Partial Rebreathing Device Migraine Non applicable NCT05546385 PAREMA1 — PArtial REbreathing for Migraine With Aura 1 TERMINATED
extended release metformin Alzheimer Phase 2/3 NCT04098666 MAP — Metformin in Alzheimer's Dementia Prevention ACTIVE_NOT_RECRUITING
Ocrelizumab SEP Phase 3 NCT05269004 OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis ACTIVE_NOT_RECRUITING
Interferon beta-1a SEP Phase 3 NCT01892722 Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis ACTIVE_NOT_RECRUITING
Atogepant 60 mg Migraine Phase 4 NCT06972056 Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study RECRUITING
Prednisone Myasthénie Phase 3 NCT00995722 Efficacy of Prednisone In the Treatment of Ocular Myasthenia TERMINATED
Zilucoplan Sclérose latérale amyotrophique Phase 2/3 NCT04297683 HEALEY ALS Platform Trial - Master Protocol ACTIVE_NOT_RECRUITING